Sarilumab 150mg or 200 mg plus Capecitabine: clinical trials recruiting now

Fewer than 3 recruiting trials found.

Phase breakdown

Conditions being studied

Recruiting trials involving Sarilumab 150mg or 200 mg plus Capecitabine

• A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
  NCT04333706 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 3 locations

Common questions

How many recruiting trials involve Sarilumab 150mg or 200 mg plus Capecitabine?

1 recruiting trial across 6 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.